Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Authors:
- María ChaparroMCMaría Chaparro
- Ana GarreAGAna Garre
- Andrea Núñez OrtizAOAndrea Núñez Ortiz
- María Teresa Diz-Lois PalomaresMPMaría Teresa Diz-Lois Palomares
- Cristina RodríguezCRCristina Rodríguez
- Sabino RiestraSRSabino Riestra
- Milagros VelaMVMilagros Vela
- José Manuel BenítezJBJosé Manuel Benítez
- Estela Fernández SalgadoESEstela Fernández Salgado
- Eugenia Sánchez RodríguezEREugenia Sánchez Rodríguez
- Vicent HernándezVHVicent Hernández
- Rocío Ferreiro-IglesiasRFRocío Ferreiro-Iglesias
Open Access
- 29 June 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2885
Abstract
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.Keywords
Funding Information
- This research has been funded by grants from the Instituto de Salud Carlos III, a grant from GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) and MSD (FIS grant PI16/01296 and PFI17/00143)
This publication has 28 references indexed in Scilit:
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialThe Lancet, 2015
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetAmerican Journal of Gastroenterology, 2015
- The global burden of IBD: from 2015 to 2025Nature Reviews Gastroenterology & Hepatology, 2015
- Incidence of inflammatory bowel disease in Iceland 1995 – 2009. A nationwide population-based studyScandinavian Journal of Gastroenterology, 2015
- Segundo Consenso Europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática Parte 1: Definiciones y diagnóstico (versión española)Revista de Gastroenterología de México, 2014
- Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohortGut, 2013
- Does Smoking Influence Crohnʼs Disease in the Biologic Era? The TABACROHN StudyInflammatory Bowel Diseases, 2013
- Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009